IONTAS has entered a collaboration with IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer. The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.    IONTAS will utilize its proprietary antibody discovery technology to help IGEM identify novel IgE antibodies against two targets.   IgE antibodies have been shown to perm...